(Gorivitug)Biosimilar Reference Antibody-GS40310

货号：GS40310

Gorivitug is an investigational SARS-CoV-2 S protein inhibitor initially developed by Regeneron Pharmaceuticals, Inc., as part of a broader antiviral portfolio. It functions as a virus internalization inhibitor. The drug is designed to bind specifically to the Spike (S) protein of the SARS-CoV-2 virus, which is responsible for mediating viral entry into human cells. By targeting the S protein, gorivitug aims to block the interaction between the virus and its cellular receptor, angiotensin-converting enzyme 2 (ACE2), or interfere with the subsequent conformational changes required for membrane fusion. This mechanism prevents the virus from internalizing and initiating infection within host cells.